

病理診断	Question	検索式 (PubMed抜粋)
総説1	intrinsic subtype分類、分子生物学的リスク分類と病理診断	((((("Breast Neoplasms/pathology"[MH] OR "Breast Neoplasms/genetics"[MAJR] OR "Breast Neoplasms/therapy"[MAJR]) AND ("Receptors, estrogen"[MH] OR "Receptors, Progesterone"[MH] OR "Receptor, ErbB-2"[MH] OR HER2[TIAB]) OR ("Precision Medicine"[MAJR] OR Immunohistochemistry[MAJR] OR (intrinsic[TIAB] AND subtype*[TIAB]) OR luminal[TIAB]))) AND ("Combined Modality Therapy"[MH] OR "Gene Expression"[MAJR])) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR (clinical[TIAB] AND benefit*[TIAB]) OR Prognos*[TIAB] OR trastuzumab[TIAB]))) AND ("Chemotherapy, Adjuvant"[MH] OR (adjuvant[TIAB] OR endocrine[TIAB] OR system*[TIAB]) AND (therap*[TIAB] OR treatment*[TIAB])) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA])) AND ((2016/01/01[DP] : 2021/03/31[DP]))
総説2	病理組織検体の適切な取扱いについて	((((("Breast Neoplasms/pathology"[MH] OR "Breast Neoplasms/chemistry"[MH]) AND (Immunohistochemistry[MH] OR immunohistochemi*[TIAB])) AND (((("Receptors, estrogen"[MH] OR "Receptors, Progesterone"[MH] OR (hormon*[TIAB] OR estrogen[TIAB] OR progesterone[TIAB]) AND receptor*[TIAB]) OR ("Receptor, ErbB-2"[MH] OR "human epidermal growth factor receptor"[TIAB] OR HER2[TIAB] OR Her-2[TIAB])) OR ("Ki-67 Antigen"[MH] AND (subtyp*[TIAB] OR "Biomarkers, Tumor"[MH])))) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR "Time Factors"[MH] OR "Tissue Fixation"[MH]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA])) AND ((2016/01/01[DP]:2021/03/31[DP]))
総説3	浸潤性乳管癌の病理学的グレード分類	((((("Breast Neoplasms/Pathology"[MAJR] OR ("Neoplasm Invasiveness"[MAJR] AND breast[TIAB])) AND (((nuclear[TIAB] OR histologic*[TIAB]) AND (grad*[TIAB]) OR histopathologic*classificat*[TIAB]))) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR Prognosis[MH] OR prognos*[TIAB]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA])) AND ((2016/01/01[DP]:2021/03/31[DP]))

<p>総説4</p>	<p>細胞診や針生検で良悪性の鑑別が困難な病変の取り扱いについて</p>	<p>((((( "Breast Neoplasms/diagnosis"[MH] OR "Breast Neoplasms/pathology"[MH] )) AND (( "Breast/diagnosis"[MH] OR "Breast/pathology"[MH] ))) OR ((breast[TIAB]) AND ((pathology[TIAB]) OR (diagnosis[TIAB])))) AND (((atypi*[TIAB] AND (ductal[TIAB] OR lobular[TIAB]) AND hyperplasia[TIAB]) OR "columnar cell lesion"[TIAB] OR "flat epithelial atypia"[TIAB] OR "lobular neoplasia"[TIAB] OR FEA[TIAB] OR ADH[TIAB] OR ALH[TIAB]))) AND (((("Biopsy, Needle"[MH] OR "Image-Guided Biopsy"[MH]) AND Diagnosis[MH]) OR patholog*[TIAB] OR "Disease Progression"[MH]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA])) AND ((2016/01/01[DP]:2021/03/31[DP]))</p>
<p>総説5</p>	<p>乳管内増殖性病変の良悪性診断に対する、免疫組織化学法の有用性</p>	<p>(((((("Breast/pathology"[MH] OR "Carcinoma, Intraductal, Noninfiltrating/pathology"[MH] OR "Carcinoma, Intraductal, Noninfiltrating/diagnosis"[MH]) OR ((DCIS[TIAB] OR "Ductal Carcinoma in Situ"[TIAB]))) AND (Immunohistochemistry[MH] OR immunohistochemi*[TIAB])) AND ("Receptors, estrogen"[MH] OR "Receptors, Progesterone"[MH] OR ((estrogen receptor*[TIAB] OR progesterone receptor*[TIAB]) OR (cytokeratin*[TIAB] OR chromogranin*[TIAB] OR synaptophysin[TIAB] OR neuroendocrine[TIAB])) AND (myoepitheli*[TIAB] OR hyperplasia[TIAB]) OR lesion*[TIAB])) AND (((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB]) OR ("Neoplasm Invasiveness"[MH] OR "Neoplasm Metastasis"[MH])) OR "Reproducibility of Results"[MH] NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP]:2021/03/31[DP]))</p>
<p>総説6</p>	<p>乳癌の転移再発が疑われる病変の病理診断に免疫組織化学法は有用か？（堀井先生）</p>	<p>(((((("Breast Neoplasms/pathology"[MAJR]) AND (Immunohistochemistry[MH] OR immunohistochemi*[TIAB])) AND (((metastasis[TIAB] OR metastatic[TIAB]) OR (recurrence[TIAB] OR recurrent[TIAB])) AND distant[TIAB]) OR ("Receptors, Estrogen"[MH] OR "Receptors, Progesterone"[MH] OR estrogen receptor*[TIAB] OR progesterone receptor*[TIAB] OR "GATA3 Transcription Factor"[MH]))) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP]:2021/03/31[DP]))</p>

BQ1	<p>乳房の病変の確定診断のために、穿刺吸引細胞診(FNA),針生検(CNB),吸引式乳房組織政権(VAB)のいずれのアプローチを最初に行うのがよいか？</p>	<p>((("Breast Neoplasms/diagnosis"[MH] OR "Breast Neoplasms/pathology"[MH] OR "Breast Neoplasms/cytology"[MH])) AND ("Biopsy, Needle"[MAJR] OR ("Image-Guided Biopsy"[MAJR] AND (needle[TIAB] OR vacuum[TIAB])))) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP] : 2021/03/31[DP]))</p>
BQ2	<p>術前化学療法後、病理組織学的に治療効果を判定することは勧められるか？</p>	<p>(((((("Breast Neoplasms/therapy"[MH] OR "Breast Neoplasms/pathology"[MAJR]) AND ("Neoadjuvant Therapy"[MH])) OR (breast cancer[TIAB] AND (neoadjuvant chemotherapy[TIAB] OR primary chemotherapy[TIAB] OR preoperative chemotherapy[TIAB]))) AND ("histological therapeutic effect"[TIAB] OR "pathological complete response"[TIAB])) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR predict*[TIAB] OR prognos*[TIAB]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP] : 2021/03/31[DP]))</p>
BQ3	<p>ホルモン受容体検査はどのような目的で、どのように行うか？</p>	<p>(((((("Breast Neoplasms/pathology"[MH] OR "Breast Neoplasms/therapy"[MH] OR "Breast Neoplasms/metabolism"[MH]) OR (breast cancer[TIAB])) AND ("Receptors, estrogen"[MH] OR "Receptors, Progesterone"[MH] OR (hormon*[TIAB] OR estrogen[TIAB] OR progesterone[TIAB]) AND receptor*[TIAB])) AND (Immunohistochemistry[MH] OR immunohistochemi*[TIAB])) AND (("Antineoplastic Agents, Hormonal"[MH] OR "Antineoplastic Agents, Hormonal" [PA]) OR ((adjuvant[TIAB] OR endocrine[TIAB]) AND therap*[TIAB]))) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR "Survival Analysis"[MH] OR predict*[TIAB] OR prognos*[TIAB] OR "cut off"[TIAB]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP] : 2021/03/31[DP]))</p>

BQ4	HER2検査はどのような目的で、どのように行うか？	<p>(((((("Breast Neoplasms/pathology"[MH] OR "Breast Neoplasms/diagnosis"[MH]) AND ("Receptor, ErbB-2"[MAJR])) OR (breast cancer[TIAB] AND (("human epidermal growth factor receptor"[TIAB]) OR (HER2[TIAB] OR Her-2[TIAB])))) AND ((Immunohistochemistry[MH]) OR ((fluorescence[TIAB] OR chromogenic[TIAB] OR silver[TIAB] OR dual[TIAB]) AND "in situ hybridization"[TIAB]) OR FISH[TIAB] OR CISH[TIAB] OR SISH[TIAB] OR DISH[TIAB]))) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR predictive factor[TIAB] OR prognostic factor[TIAB] OR diagnos*[TIAB] OR trastuzumab[TIAB]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP] : 2021/03/31[DP]))</p>
BQ5	乳房部分切除術の病理組織学的断端診断はどのように行うか？	<p>(((((("Breast Neoplasms/pathology"[MH] OR "Breast Neoplasms/surgery"[MH]) AND ("Mastectomy, Segmental"[MH])) OR (breast conserv*[TIAB] AND (therapy[TIAB] OR surgery[TIAB]))) AND ("Frozen Sections"[MH] OR margin*[TIAB])) AND (("Neoplasm Invasiveness"[MH] OR "Neoplasm Recurrence, Local"[MH] OR "Neoplasm, Residual"[MH]) OR (ipsilateral breast tumor recurrence[TIAB]))) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR Prognosis[MH] OR Survival Analysis[MH] OR intraoperative[TIAB]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP] : 2021/03/31[DP]))</p>
BQ6	センチネルリンパ節の病理学的検索はどのように行うか？	<p>(((((("Breast Neoplasms/pathology"[MH]) AND ("Lymph Nodes/pathology"[MH] OR ("Neoplasm Micrometastasis"[MH] OR "Lymphatic Metastasis"[MH]) OR (metasta*[TIAB] OR "isolated tumor cells"[TIAB]))) AND (Immunohistochemistry[MH] OR "Nucleic Acid Amplification Techniques"[MH] OR OSNA[TIAB] OR "polymerase chain reaction"[TIAB] OR "Lymph Node Excision"[MH])) AND ("sentinel lymph node"[TW] OR "Sentinel Lymph Node Biopsy"[MH])) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB]) OR "Prognosis"[MH]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP] : 2021/03/31[DP]))</p>

BQ7	非浸潤性乳管癌(DCIS)で核グレードや面泡壊死の有無を評価することは勧められるか？	(((("Carcinoma, Intraductal, Noninfiltrating"[MH] OR "Ductal Carcinoma in Situ"[TIAB] OR DCIS[TIAB]) AND ("Culture Techniques"[MH] OR "nuclear grade"[TIAB] OR comedo[TIAB] OR "Van Nuys prognostic index"[TIAB])) AND (((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB]) OR Prognosis[MH] OR classification[TW]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP] : 2021/03/31[DP])))
BQ8	針生検検体を用いたホルモン受容体やHER2の検索は勧められるか？	(("Breast Neoplasms"[MH] AND ("Biopsy, Large-Core Needle"[MH] OR ("core needle"[TIAB] AND biops*[TIAB]))) AND (("Receptor, ErbB-2"[MH] OR "Receptors, Estrogen"[MH] OR "Receptors, Progesterone"[MH] OR "Biomarkers, Tumor"[MH]) OR ((estrogen[TIAB] OR progesterone[TIAB]) AND receptor*[TIAB]) OR (HER2[TIAB] OR Her-2[TIAB])) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA])) AND ((2016/01/01[DP] : 2021/03/31[DP]))
FRQ1	浸潤性乳癌におけるKi67評価はどのような症例に勧められるか？評価方法はどのようにしたらよいのか？	(((("Breast Neoplasms"[MH] OR ("Neoplasm Invasiveness"[MH] AND breast[TIAB])) AND ("Ki-67 Antigen"[MH] AND (subtyp*[TIAB] OR "Biomarkers, Tumor"[MH]) AND Prognosis[MH])) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR Diagnosis[MH]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP] : 2021/03/31[DP]))
FRQ2	非浸潤性乳管癌におけるホルモン受容体やHER2の検索は勧められるか？	((((("Carcinoma, Intraductal, Noninfiltrating/diagnosis"[MH] OR "Carcinoma, Intraductal, Noninfiltrating/pathology"[MH]) OR (DCIS[TIAB] OR "Ductal Carcinoma In Situ"[TIAB])) AND ("Neoplasm Recurrence, Local"[MH] OR "Neoplasm Invasiveness"[MH] OR microinvasi*[TIAB] OR recurren*[TIAB])) AND (("Receptor, ErbB-2"[MH] OR "Receptors, Estrogen"[MH] OR "Receptors, Progesterone"[MH] OR "Biomarkers, Tumor"[MH]) OR ((estrogen[TIAB] OR progesterone[TIAB]) AND receptor*[TIAB]) OR (HER2[TIAB] OR Her-2[TIAB]))) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR Prognosis[MH] OR "Survival Analysis"[MH]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP] : 2021/03/31[DP]))

FRQ3	再発乳癌における治療方針決定にセルブロック標本を用いた検討は勧められるか？	(("Breast Neoplasms"[MH] OR ("breast cancer"[TIAB] OR "breast carcinoma"[TIAB])) AND (((Immunohistochemistry[MH] OR immunohistochemi*[TIAB] OR cytology[TW]) AND (fluid*[TIAB] OR ascites[TIAB] OR effusion*[TIAB])) OR (cell block*[TIAB])) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA])) AND ((2016/01/01[DP] : 2021/03/31[DP]))
FRQ4	浸潤性乳管癌における腫瘍浸潤リンパ球(TIL)の診断は有用か？	(((("Breast Neoplasms"[MH]) AND ("Lymphocytes, Tumor-Infiltrating"[MH])) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR "Diagnosis"[MH] OR validity[TIAB] OR evaluat*[TIAB]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((2016/01/01[DP] : 2021/03/31[DP]))
FRQ5	浸潤性乳癌におけるPD-L1検査はどのように行うか？	(((("Triple Negative Breast Neoplasms"[MH]) AND (PD-L1[TIAB] OR PD-1[TIAB] OR "Immune Checkpoint Inhibitors"[MH] OR "Antibodies, Monoclonal"[MH])) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR "Diagnosis"[MH] OR validity[TIAB] OR evaluat*[TIAB]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA]))) AND ((0001/01/01[DP] : 2021/03/31[DP]))
FRQ6	がん遺伝子パネル検査にはどのような種類があり、どのような検体を提出する必要があるか？	((((("Neoplasms/diagnosis"[MH] OR "Neoplasms/genetics"[MAJR]) AND ("Precision Medicine"[MH] OR "Molecular Targeted Therapy"[MH] OR "High-Throughput Nucleotide Sequencing"[MAJR] OR "next generation sequencing"[TIAB] OR NCC oncopanel[TIAB] OR OncoGuide[TIAB] OR FoundationOne[TIAB])) AND ((sensitiv*[TIAB] OR "Sensitivity and Specificity"[MH] OR (predictive[TIAB] AND value*[TIAB]) OR "Predictive Value of Tests"[MH] OR accuracy*[TIAB] OR "Prognosis"[MH] OR validity[TIAB] OR evaluat*[TIAB]))) AND ("Patient Selection"[MH] OR specimen*[TIAB] OR tissue[TIAB])) AND (Genomics[MH] OR genom*[TIAB]) NOT (Animals[MH] NOT Humans[MH]) AND (English[LA] OR Japanese[LA])) AND ((0001/01/01[DP] : 2021/03/31[DP]))